# HeartBeam Joins European Consortium to Test Portable ECG System

- URL: https://stocks.freetheai.org/news/heartbeam-joins-european-consortium-to-test-portable-ecg-system-880740
- Published: 2026-10-15T12:31:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NASDAQ:BEAT](https://stocks.freetheai.org/symbols/NASDAQ-BEAT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

HeartBeam, Inc. (BEAT) has joined the EXIT-CVD research consortium, a 27.6 million euro European initiative focused on improving cardiovascular care. As part of the public-private partnership, HeartBeam will lead the HEART-CHECK study to test its portable electrocardiogram technology on patients recently discharged after acute coronary syndrome. HeartBeam is providing devices and clinical expertise as an in-kind contribution.

The research allows HeartBeam to evaluate whether clinical-grade heart monitoring outside of healthcare facilities can help physicians spot recurrent cardiac events earlier. The HeartBeam System records electrical signals in three dimensions from home. While the device is approved in the U.S. for arrhythmia assessment, its use for heart attack detection is investigational, and it is not yet CE marked in Europe.

Investors will keep an eye on clinical trial progress and regulatory developments. HeartBeam recently earned FDA Breakthrough Device Designation for home heart attack assessment, which remains its main regulatory target. Market participants will watch whether findings from the European study support broader regulatory approvals and commercial adoption over time.

## Key points

- HeartBeam, Inc. (BEAT) joined the 27.6 million euro European EXIT-CVD research consortium.
- The company will lead the HEART-CHECK clinical study evaluating its portable ECG system in high-risk cardiac patients.
- HeartBeam is contributing devices and clinical expertise in-kind to the 42-partner European initiative.
- The HeartBeam System is FDA cleared for arrhythmia assessment but remains investigational for heart attack detection.

## Questions and answers

### What is HeartBeam's role in the EXIT-CVD project?

HeartBeam is leading the HEART-CHECK study within the project, testing its portable ECG technology on high-risk patients after acute coronary syndrome using in-kind device and expertise contributions.

### Is HeartBeam's system FDA cleared for heart attack assessment?

The system is FDA cleared for arrhythmia assessment, but its use for heart attack detection is investigational. It recently received FDA Breakthrough Device Designation for home heart attack assessment.